-
- Sarah R. Leist
- The University of North Carolina at Chapel Hill Department of Epidemiology , , Chapel Hill, NC 27599 , USA
-
- Alexandra Schäfer
- The University of North Carolina at Chapel Hill Department of Epidemiology , , Chapel Hill, NC 27599 , USA
-
- David R. Martinez
- The University of North Carolina at Chapel Hill Department of Epidemiology , , Chapel Hill, NC 27599 , USA
説明
<jats:title>ABSTRACT</jats:title> <jats:p>The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.</jats:p>
収録刊行物
-
- Disease Models & Mechanisms
-
Disease Models & Mechanisms 13 (9), dmm046581-, 2020-09-01
The Company of Biologists